GeneDx (WGS) Projected to Post Earnings on Tuesday

GeneDx (NASDAQ:WGS) is anticipated to post its quarterly earnings results before the market opens on Tuesday, February 18th. Analysts expect GeneDx to post earnings of $0.04 per share and revenue of $82.24 million for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

GeneDx Price Performance

NASDAQ WGS opened at $76.35 on Friday. GeneDx has a 52 week low of $4.34 and a 52 week high of $98.87. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. The stock has a market cap of $2.10 billion, a price-to-earnings ratio of -24.55 and a beta of 2.01. The company has a 50-day moving average price of $76.41 and a two-hundred day moving average price of $60.70.

Analyst Ratings Changes

Several research analysts have commented on the stock. Craig Hallum upped their target price on shares of GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. TD Cowen upped their target price on shares of GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research report on Tuesday, January 7th. Wells Fargo & Company upped their target price on shares of GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 30th. Finally, The Goldman Sachs Group upped their target price on shares of GeneDx from $54.00 to $70.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $70.67.

Insider Activity

In related news, Director Jason Ryan sold 31,510 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $71.28, for a total value of $2,246,032.80. Following the completion of the sale, the director now owns 15,490 shares in the company, valued at approximately $1,104,127.20. This represents a 67.04 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder School Of Medicine At Mo Icahn sold 126,782 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $70.78, for a total transaction of $8,973,629.96. Following the completion of the sale, the insider now owns 2,719,692 shares of the company’s stock, valued at approximately $192,499,799.76. This trade represents a 4.45 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 320,202 shares of company stock worth $25,011,778 over the last three months. Corporate insiders own 27.30% of the company’s stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.